×




Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A) Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A) case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A) case study is a Harvard Business School (HBR) case study written by Barbara S. Petitt. The Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A) (referred as “Sanofi Aventis” from here on) case study provides evaluation & decision scenario in field of Finance & Accounting. It also touches upon business topics such as - Value proposition, .

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A) Case Study


This is a Thunderbird Case Study.It was late on Thursday, April 22, 2004, and Jean-Francois Dehecq, the Chief Executive Officer (CEO) of Sanofi-Synthei€ˆlabo (Sanofi), France's second largest pharmaceutical company, was sitting in his office thinking about what had happened over the last three months. On January 26, 2004, he had launched a hostile tender offer to acquire Aventis, France's largest pharmaceutical company. The merger between Sanofi and Aventis would have created the world's third largest pharmaceutical company, closing the gap with U.S.-based Pfizer and U.K.-based GlaxoSmith-Kline (GSK). Jean-Francois Dehecq had offered a‚¬48.6 billion, but his offer had been rejected by Aventis's Supervisory Board. Since the end of January, Aventis had been fighting back, launching a poison pill and inviting Novartis, Switzerland's largest pharmaceutical company, to act as a white knight.


Case Authors : Barbara S. Petitt

Topic : Finance & Accounting

Related Areas :




Calculating Net Present Value (NPV) at 6% for Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A) Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10012054) -10012054 - -
Year 1 3450126 -6561928 3450126 0.9434 3254836
Year 2 3971620 -2590308 7421746 0.89 3534728
Year 3 3974674 1384366 11396420 0.8396 3337213
Year 4 3247479 4631845 14643899 0.7921 2572308
TOTAL 14643899 12699084




The Net Present Value at 6% discount rate is 2687030

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Profitability Index
2. Payback Period
3. Internal Rate of Return
4. Net Present Value

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Sanofi Aventis shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Sanofi Aventis have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.






Formula and Steps to Calculate Net Present Value (NPV) of Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A)

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Finance & Accounting Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Sanofi Aventis often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Sanofi Aventis needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10012054) -10012054 - -
Year 1 3450126 -6561928 3450126 0.8696 3000110
Year 2 3971620 -2590308 7421746 0.7561 3003115
Year 3 3974674 1384366 11396420 0.6575 2613413
Year 4 3247479 4631845 14643899 0.5718 1856757
TOTAL 10473394


The Net NPV after 4 years is 461340

(10473394 - 10012054 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10012054) -10012054 - -
Year 1 3450126 -6561928 3450126 0.8333 2875105
Year 2 3971620 -2590308 7421746 0.6944 2758069
Year 3 3974674 1384366 11396420 0.5787 2300159
Year 4 3247479 4631845 14643899 0.4823 1566107
TOTAL 9499440


The Net NPV after 4 years is -512614

At 20% discount rate the NPV is negative (9499440 - 10012054 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Sanofi Aventis to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Sanofi Aventis has a NPV value higher than Zero then finance managers at Sanofi Aventis can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Sanofi Aventis, then the stock price of the Sanofi Aventis should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Sanofi Aventis should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A)

References & Further Readings

Barbara S. Petitt (2018), "Sanofi-Synthelabo and Aventis: The Birth of a National Champion (A) Harvard Business Review Case Study. Published by HBR Publications.


Hosoda SWOT Analysis / TOWS Matrix

Capital Goods , Construction Services


China Glass Holdings SWOT Analysis / TOWS Matrix

Capital Goods , Constr. - Supplies & Fixtures


Gaussin SWOT Analysis / TOWS Matrix

Capital Goods , Misc. Capital Goods


Amgen SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


Boldface Group, Inc. SWOT Analysis / TOWS Matrix

Consumer/Non-Cyclical , Personal & Household Prods.


PCCS SWOT Analysis / TOWS Matrix

Consumer Cyclical , Apparel/Accessories